Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

PBMs’ Impact On Drug Prices Probed By House Committee Leaders

Executive Summary

Letter to seven pharmacy benefit managers seeks insight into pros and cons of practices, suggesting that policymakers understand PBMs bring value in lowering costs but that some activities are counterproductive.

Advertisement

Related Content

Pharmacy “Gag Clause” Bills: Another Simple Fix For Drug Pricing That Is Not So Simple
Medicare Part D Plans Can Start Negotiating Indication-Based Pricing This Fall
HHS Advancing Attack On Rebates With Proposal To Revoke Safe Harbor
Drug Firms Fear PBM ‘Discrimination’ Over List Price Reductions, Azar Tells Hearing
Pharma’s Blame-The-Middleman Strategy Pays Off – For Now
Drug Pricing: US House, Senate, Taking Bicameral Go-Slow Approach

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS123789

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel